keyword
MENU ▼
Read by QxMD icon Read
search

Real-world rcc

keyword
https://www.readbyqxmd.com/read/29780111/life-threatening-hyperkalemia-associated-with-axitinib-treatment-in-patients-with-recurrent-renal-carcinoma-a-case-report
#1
Shigeo Godo, Yoshitaro Yoshida, Naoki Kawamorita, Koji Mitsuzuka, Yu Kawazoe, Motoo Fujita, Daisuke Kudo, Ryosuke Nomura, Hiroaki Shimokawa, Shigeki Kushimoto
Axitinib has emerged as a promising antineoplastic agent for the treatment of advanced renal cell carcinoma. Although the administration of axitinib was well-tolerated in clinical trials, the real-world safety and tolerability remain unverified. We herein report a patient with metastatic renal cell carcinoma who suddenly developed life-threatening hyperkalemia following the initiation of axitinib treatment. Although hyperkalemia has been reported with an incidence of <10%, acute severe hyperkalemia may be a considerably critical adverse event of axitinib therapy, especially in patients with risk factors for hyperkalemia...
May 18, 2018: Internal Medicine
https://www.readbyqxmd.com/read/29753637/safety-and-efficacy-of-cabozantinib-in-metastatic-renal-cell-carcinoma-real-world-data-from-an-italian-managed-access-program
#2
Giuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, Enrico Cortesi, Giuseppe Fornarini, Gaetano Facchini, Giacomo Cartenì, Roberto Sabbatini, Gabriella Del Bene, Luca Galli, Claudia Caserta, Andrea Giovanni Multari, Marco Bregni, Francesco Massari, Sebastiano Buti, Ugo De Giorgi, Fable Zustovich, Michele Milella, Fabio Calabrò, Maria Laura Mancini, Giampaolo Tortora, Claudio Vernieri, Daniele Santini, Mariella Sorarù, Riccardo Ricotta, Cristina Masini, Marcello Tucci, Stefano Luzi Fedeli, Cinzia Ortega, Antonella Mecozzi, Raffaele Ratta, Cora N Sternberg, Elena Verzoni
BACKGROUND: The randomized phase 3 METEOR study confirmed a survival benefit of cabozantinib over everolimus in patients with metastatic renal-cell carcinoma (mRCC) with disease that progressed after treatment with at least one previous antiangiogenic inhibitor. The aim of this analysis was to evaluate the safety and activity of cabozantinib in an unselected population. METHODS: Data were collected across 24 Italian centers. Cabozantinib therapy was initiated at physician request between September and December 2016...
April 19, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29721212/efficacy-and-safety-of-sorafenib-for-advanced-renal-cell-carcinoma-real-world-data-of-patients-with-renal-impairment
#3
Katsunori Tatsugami, Mototsugu Oya, Koki Kabu, Hideyuki Akaza
Background: We retrospectively analysed the efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with renal impairment. Methods: Patients were divided into two groups by an estimated glomerular filtration rate (eGFR) cut-off of 45 mL/min/1.73 m2 . Background factors considered to affect prognosis were well balanced by propensity score matching between the groups. Demographics, dose modification, adverse events, tumour response, progression-free survival, and renal function (eGFR) were evaluated...
April 10, 2018: Oncotarget
https://www.readbyqxmd.com/read/29714652/real-world-evidence-in-metastatic-renal-cell-carcinoma
#4
Jeffrey Graham, Daniel Yc Heng
Real-world evidence has played an important role in expanding our knowledge on the treatment and prognostication of advanced renal cell carcinoma. This type of data has been particularly helpful in providing a better understanding of groups that are traditionally excluded from randomized controlled trials. The International mRCC Database Consortium (IMDC) represents the largest collection of real-world data on patients with advanced kidney cancer treated with targeted therapies. The IMDC prognostic model has been used to stratify patients in contemporary clinical trials and to provide risk-directed treatment selection in everyday clinical practice...
March 1, 2018: Tumori
https://www.readbyqxmd.com/read/29682181/high-competing-risks-minimize-real-world-utility-of-adjuvant-targeted-therapy-in-renal-cell-carcinoma-a-population-based-analysis
#5
Thenappan Chandrasekar, Zachary Klaassen, Hanan Goldberg, Rashid K Sayyid, Girish S Kulkarni, Neil E Fleshner
Objective: To utilize a population-based approach to address the role of adjuvant TT in the management of RCC. Methods: Patients with RCC (2006-2013) in the SEER database were stratified by metastatic disease at the time of diagnosis (cM0/cM1). cM0 patients following surgical excision were stratified into low and high-risk (ASSURE and S-TRAC criteria). Multivariable analyses performed to identify predictors of TT receipt; Fine and Gray competing risks analyses used to identify predictors of cancer-specific mortality (CSM)...
March 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29662544/sunitinib-in-the-treatment-of-renal-cell-carcinoma-an-update-on-recent-evidence
#6
REVIEW
Mimma Rizzo, Camillo Porta
Sunitinib is a multitarget tyrosine kinase inhibitor endowed mainly by antiangiogenic effects, although an indirect inhibitory effect on tumor growth and, more recently, a complex activity on antitumor immune response has been described. From approval by the US Food and Drug Administration (FDA) in January 2006, sunitinib represents a key molecule in the treatment of metastatic renal cell carcinoma (mRCC) due to the peculiar molecular pathogenesis of this neoplasm. Over the past 10 years, clinical trials and real-world experiences helped clinicians to understand how, when and for how long to use sunitinib...
August 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/29503245/pattern-of-care-study-in-metastatic-renal-cell-carcinoma-in-the-preimmunotherapy-era-in-switzerland
#7
Nadja Sandmeier, Sacha I Rothschild, Christian Rothermundt, Richard Cathomas, Julian Schardt, Dominik Berthold, Philippe von Burg, Beat Müller, Jörg Beyer, Deborah R Vogt, Frank Stenner
INTRODUCTION: In metastatic renal-cell carcinoma (mRCC), physicians have a plethora of therapeutic choices, with the latest addition of checkpoint inhibitors. However, many questions regarding the best use of the respective drugs remain unanswered. Therefore, it is important to examine and summarize the outcome of real-world experiences to understand the practical value of the various drugs in daily use and foster optimal treatment algorithms for patients with renal-cell carcinoma. We sought to describe the pattern of care in mRCC under circumstances with access to all therapeutic options for patients...
February 2, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29478961/exposure-to-multiple-lines-of-treatment-and-survival-of-patients-with-metastatic-renal-cell-carcinoma-a-real-world-analysis
#8
Raffaele Ratta, Elena Verzoni, Massimo Di Maio, Paolo Grassi, Maurizio Colecchia, Giovanni Fucà, Filippo de Braud, Giuseppe Procopio
BACKGROUND: The purpose of the present retrospective analysis was to describe the trends in exposure to multiple lines of treatment and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) who started therapy in 2 different periods (period 1, 2004-2010; and period 2, 2011-2017). PATIENTS AND METHODS: The proportion of patients who received subsequent lines of treatment after disease progression was compared between the 2 groups. OS was measured from the start of first-line treatment for metastatic disease to death or the last follow-up examination...
February 5, 2018: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29466966/real-life-patterns-of-care-and-progression-free-survival-in-metastatic-renal-cell-carcinoma-patients-retrospective-analysis-of-cross-sectional-data
#9
Rana Maroun, Laura Mitrofan, Laure Benjamin, Gaelle Nachbaur, Franck Maunoury, Philippe Le Jeunne, Isabelle Durand-Zaleski
BACKGROUND: Patient characteristics and survival outcomes in randomized trials may be different from those in real-life clinical practice. The objective of this study was to describe treatment pathways, safety, drug costs and survival in patients with metastatic Renal Cell Carcinoma (mRCC) in a real world setting. METHODS: A retrospective analysis was performed using IQVIA real world oncology cross-sectional survey data, a retrospective treatment database collecting anonymized patient-level data in Europe...
February 21, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29325434/collection-of-real-world-data-on-nivolumab-s-effectiveness-in-renal-cell-carcinoma-rationale-for-an-observational-study
#10
Jens Bedke, Marc-Oliver Grimm, Viktor Grünwald
Renal cell carcinoma (RCC) represents the seventh (men) respectively tenth (women) most frequent cancer in western countries. After one or more lines of VEGF-targeted therapy, immunotherapy with nivolumab is strongly recommended in patients with metastatic RCC. Nivolumab is the first, and so far, only approved programmed death 1 (PD-1) immune checkpoint inhibitor to demonstrate a gain in overall survival in RCC. We describe herein design and rationale of trial CA209653 ('NIS NORA'), a prospective, noninterventional cohort study investigating the effectiveness of nivolumab...
January 12, 2018: Future Oncology
https://www.readbyqxmd.com/read/29279098/systematic-review-and-survival-meta-analysis-of-real-world-evidence-on-first-line-pazopanib-for-metastatic-renal-cell-carcinoma
#11
REVIEW
Miguel A Climent, José Muñoz-Langa, Laura Basterretxea-Badiola, Carmen Santander-Lobera
A systematic review was conducted to identify real world studies reporting outcomes after first-line pazopanib in patients with metastatic renal cell carcinoma. Studies had to be observational and report survival data in terms of progression-free survival and overall survival in order to conduct meta-analysis techniques. These real-world data were compared to those obtained in the phase II and III randomized controlled trials of pazopanib. Real world evidence showed that the clinical and safety outcomes were consistent with those observed in the clinical trials despite the inclusion of unselected patients with a wide spectrum of prognostic features and comorbidities...
January 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29238223/the-effect-of-medication-nonadherence-on-progression-free-survival-among-patients-with-renal-cell-carcinoma
#12
Jason Shafrin, Jeffrey Sullivan, Jacquelyn W Chou, Michael N Neely, Justin F Doan, J Ross Maclean
Objective: To examine how observed medication nonadherence to 2 second-line, oral anticancer medications (axitinib and everolimus) affects progression-free survival (PFS) among patients with renal cell carcinoma. Methods: We used an adherence-exposure-outcome model to simulate the impact of adherence on PFS. Using a pharmacokinetic/pharmacodynamic (PK/PD) population model, we simulated drug exposure measured by area under the plasma concentration-time curve (AUC) and minimum blood or trough concentration (Cmin ) under 2 scenarios: 1) optimal adherence and 2) real-world adherence...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/29173270/clinical-outcomes-of-the-sequential-use-of-pazopanib-followed-by-everolimus-for-the-treatment-of-metastatic-renal-cell-carcinoma-a-multicentre-study-in-korea
#13
Jeong Ho Kim, Wan Lee, Tae Nam Kim, Jong Kil Nam, Tae Hyo Kim, Ki Soo Lee
INTRODUCTION: The aim of this study was to investigate the real-world clinical outcomes of first-line pazopanib and second-line everolimus in Korean patients with metastatic renal cell carcinoma (mRCC). METHODS: Data of patients who had mRCC with clear-cell component between 2001 and 2015 at multiple institutions were collected retrospectively. To be included in the analysis, patients had to meet the following criteria: age ≥18 years; received first-line targeted therapy with pazopanib; and received second-line targeted therapy with everolimus...
January 2018: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/29089775/practical-management-of-adverse-events-associated-with-cabozantinib-treatment-in-patients-with-renal-cell-carcinoma
#14
REVIEW
Benjamin S Gerendash, Patricia A Creel
Cabozantinib is an oral tyrosine-kinase inhibitor whose targets include VEGFR, MET, and AXL. Cabozantinib is approved for the treatment of patients with advanced clear-cell renal-cell carcinoma (RCC) who have received prior antiangiogenic therapy. In the pivotal Phase III trial of second-line RCC, cabozantinib was associated with a significant improvement in overall survival, progression-free survival, and antitumor response compared with everolimus. Adverse events (AEs) were common for patients receiving cabozantinib, but were effectively managed with supportive care and dose modifications, as discontinuations of cabozantinib due to an AE were infrequent...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29076108/clinical-and-economic-outcomes-in-elderly-advanced-renal-cell-carcinoma-patients-starting-pazopanib-or-sunitinib-treatment-a-retrospective-medicare-claims-analysis
#15
Nicholas J Vogelzang, Sumanta K Pal, Sameer R Ghate, Elyse Swallow, Nanxin Li, Miranda Peeples, Miriam L Zichlin, Mark K Meiselbach, Jose Ricardo Perez, Neeraj Agarwal
INTRODUCTION: Studies indicate similar survival and toxicity between pazopanib and sunitinib, but few have examined real-world outcomes among elderly patients with advanced renal cell carcinoma (RCC). The purpose of this retrospective claims analysis was to assess real-world overall survival (OS), healthcare resource utilization (HRU), and healthcare costs (both all-cause and associated with RCC diagnosis) among elderly advanced RCC patients starting pazopanib or sunitinib treatment. METHODS: Advanced RCC patients aged 65 years or older who started first-line treatment with pazopanib or sunitinib (index drug; the initiation date was the index date) were identified from the 100% Medicare database plus Part D linkage (January 1, 2006 to December 31, 2014)...
November 2017: Advances in Therapy
https://www.readbyqxmd.com/read/29062235/real-world-experience-of-everolimus-as-second-line-treatment-in-metastatic-renal-cell-cancer-after-failure-of-pazopanib
#16
Konstantinos Koutsoukos, Aristotelis Bamias, Kimon Tzannis, Marta Espinosa Montaño, Vasiliki Bozionelou, Christos Christodoulou, Dimitra Stefanou, Haralabos Kalofonos, Ignacio Duran, Konstantinos Papazisis
AIM: We aimed to provide real-life data on the outcomes of metastatic renal cell carcinoma (mRCC) patients treated with everolimus as second-line treatment after failure of first-line pazopanib. PATIENTS AND METHODS: Data from the medical charts of mRCC patients from 8 centers in Greece and Spain were reviewed. All patients had received or were continuing to receive second-line everolimus treatment after failure of first-line treatment with pazopanib. No other previous therapies were allowed...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29051995/exposure-survival-analyses-of-pazopanib-in-renal-cell-carcinoma-and-soft-tissue-sarcoma-patients-opportunities-for-dose-optimization
#17
R B Verheijen, L E Swart, J H Beijnen, J H M Schellens, A D R Huitema, N Steeghs
BACKGROUND: Pazopanib is an angiogenesis inhibitor approved for the treatment of renal cell carcinoma and soft tissue sarcoma. Post hoc analysis of a clinical trial demonstrated a relationship between pazopanib trough concentrations (Cmin ) and treatment efficacy. The aim of this study was to explore the pharmacokinetics and exposure-survival relationships of pazopanib in a real-world patient cohort. PATIENTS AND METHODS: Renal cell cancer and soft tissue sarcoma patients who had at least one pazopanib plasma concentration available were included...
December 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29027615/assessment-of-the-role-of-everolimus-therapy-in-patients-with-renal-cell-carcinoma-based-on-daily-routine-and-recent-research-results
#18
Anikó Maráz, András Csejtei, Judit Kocsis, Miklós Szűcs, Zsuzsanna Kahán, György Bodoky, Magdolna Dank, László Mangel, János Révész, Zoltán Varga, Lajos Géczi
Everolimus is indicated for adults with metastatic renal cell carcinoma (mRCC) after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (TKI). Currently, the therapeutic applicability of EVE has been changing. Multicenter evaluation of efficacy and safety of everolimus in daily routine and definition of patient characteristics with favorable outcome. Data of 165 patients from 9 oncology institutes in Hungary were analyzed retrospectively. Everolimus therapy was used after one TKI in 10 mg starting dose...
October 13, 2017: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/28882737/five-year-survival-of-patients-with-metastatic-renal-cell-carcinoma-in-the-russian-federation-results-from-the-rensur5-registry
#19
MULTICENTER STUDY
Ilya Tsimafeyeu, Tatiana Zolotareva, Sergei Varlamov, Ruslan Zukov, Vladislav Petkau, Mikhail Mazhbich, Galina Statsenko, Sufia Safina, Igor Zaitsev, Dina Sakaeva, Alexander Popov, Pavel Borisov, Liubov Vladimirova
BACKGROUND: The 5-year overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC) has been rarely reported. The aim of the RENSUR5 registry study was to obtain real-world data on the use of therapy for mRCC and assess the 5-year OS in the Russian population. PATIENT AND METHODS: Patients were retrospectively identified at 11 cancer centers in different regions of Russia (Astrakhan, Barnaul, Ekaterinburg, Kazan, Krasnoyarsk, Obninsk, Omsk, Rostov-on-Don, Samara, St...
December 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28798821/benchmarking-quality-for-renal-cancer-surgery-canadian-kidney-cancer-information-system-ckcis-perspective
#20
Keith A Lawson, Olli Saarela, Zhihui Liu, Luke T Lavallée, Rodney H Breau, Lori Wood, Michael A S Jewett, Anil Kapoor, Simon Tanguay, Ronald B Moore, Ricardo Rendon, Frederic Pouliot, Peter C Black, Jun Kawakami, Darrel Drachenberg, Antonio Finelli
INTRODUCTION: There is a lack of validated quality metrics to evaluate the care of patients receiving surgery for renal cell carcinoma (RCC). To address this, the Kidney Cancer Research Network of Canada defined a list of quality indicators (QI) to assess hospital-level performance. We have case-mix adjusted these QIs to benchmark RCC surgical care at Canadian academic centres. METHODS: The Canadian Kidney Cancer information system (CKCis) was used to measure six QIs: laparoscopic approach proportion (LA), partial nephrectomy proportion (PN), partial nephrectomy in patients with chronic kidney disease (CKDPN), positive margin rate (PMR), partial nephrectomy complication rate (PNCx), and warm ischemia time (WIT)...
August 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
keyword
keyword
113027
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"